# AJANTPHARM (AJANTPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/ajantpharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,557
- Change: +1.61%
- As of: 2026-09-18
- 1D return: +1.80%
- 5D return: +1.24%
- 1M return: -2.60%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Ajanta Pharma is trading at ₹3563.6, showing a mixed technical stance across different timeframes. Daily indicators suggest a bullish trend, with the price trading above key moving averages including the 20-day EMA (₹3533.3), 50-day EMA (₹3476.38), and the 200-day SMA (₹3058.08). The Supertrend indicator is also bullish on the daily chart. However, the weekly and monthly charts present an Inside Bar and a Doji pattern respectively, indicating potential consolidation or indecision. The price is currently positioned near the upper half of its 50-day and 252-day trading ranges, at 54% and 84% respectively. Recent market activity includes one positive attention event and one downside event in the last 30 days.

The stock is currently encountering resistance near ₹3575.83, which is approximately 0.34% above the current price. Key support levels are observed around ₹3552.97 (0.3% below) and ₹3526.73 (1.03% below). The stock exhibits an annualized volatility of 30% and a current drawdown of -4%. The nearest resistance at ₹3575.83 represents a near-term hurdle, while support around ₹3552.97 could provide a floor.

- Price as of September 18, 2026: ₹3563.6
- Nearest resistance level: ₹3575.83 (approx. 0.34% above current price)
- Nearest support level: ₹3552.97 (approx. 0.3% below current price)
- Daily trend indicators are bullish, with price above key moving averages (20-day EMA ₹3533.3, 50-day EMA ₹3476.38, 200-day SMA ₹3058.08).
- Weekly and monthly charts show consolidation patterns (Doji, Inside Bar), suggesting potential indecision.

- Inside Bar
- Doji
- Bearish Engulfing Reversal
- Evening Star

### News Context

The domestic pharmaceutical market demonstrated sustained growth in August, driven by price increases and new product introductions. However, concerns persist regarding the impact of weak sales volumes and potential U.S. tariffs on profit margins. A significant margin recovery is viewed as crucial for the sector's overall performance.

- Domestic pharma market growth sustained in August due to price hikes and new launches.
- Weak sales volumes and U.S. tariff uncertainty pose risks to sector margins.
- Sustained margin recovery is considered essential for sector performance.

- Domestic pharma market sustains growth momentum, but margins remain key

### What Changed

As of September 18, 2026, Ajanta Pharmaceuticals (AJANTPHARM) on the NSE is trading at ₹3563.6, a slight increase from its previous price of ₹3500.5. The provided evidence does not contain details on any new filings or news events that have occurred recently. Therefore, the primary recent development is the observed price movement.

- On September 18, 2026, the stock price for Ajanta Pharmaceuticals was ₹3563.6.
- The previous stock price recorded was ₹3500.5.

### Official Filings

Ajanta Pharma Limited has scheduled investor meetings in September 2026, including a one-on-one at the Jefferies India Forum on September 16, 2026, in New Delhi, and participation in the PL Capital Mid & Small Cap Conference 2026 on September 28, 2026, in Mumbai. The company has stated that discussions during these events will be based on publicly available information. Earlier in August 2026, the company participated in investor conferences in Singapore and Hong Kong (August 11-13, 2026) and a conference in Mumbai (August 18, 2026), also adhering to the principle of discussing only published information. On July 30, 2026, the company's Nomination & Remuneration Committee approved the allotment of 23,400 equity shares following the exercise of employee stock options. This allotment increased the company's paid-up capital to ₹24,99,18,048, comprising 12,49,59,024 equity shares of ₹2 each. The company indicated it would apply for the listing of these newly issued shares.

- Scheduled investor meetings in September 2026: September 16 (Jefferies India Forum, New Delhi) and September 28 (PL Capital Mid & Small Cap Conference, Mumbai).
- Previous investor meetings held in August 2026: August 11-13 (Singapore & Hong Kong) and August 18 (Mumbai).
- On July 30, 2026, 23,400 equity shares were allotted upon exercise of options.
- Company's paid-up capital increased to ₹24,99,18,048 following the share allotment.

- Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Ajanta Pharma Limited has informed the Exchange about |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- AJANTA PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- NAME OF PROMOTER(S) OR PACS WITH HIM : Ravi P Agrawal, trustee Ravi Agrawal Trust

### Fundamentals

Ajanta Pharmaceuticals reported revenue from operations of ₹1,625.96 crore for Q1 FY2026-27. This represents an increase from ₹1,421.64 crore in Q4 FY2025-26 and ₹1,374.84 crore in Q3 FY2025-26. Profit Before Tax (PBT) for Q1 FY2026-27 was ₹446.80 crore, up from ₹347.11 crore in Q4 FY2025-26 and ₹358.60 crore in Q3 FY2025-26. The company reported Basic Earnings Per Share (EPS) of ₹26.75 for Q1 FY2026-27, an increase from ₹21.35 in Q4 FY2025-26 and ₹21.91 in Q3 FY2025-26. Other Expenses increased sequentially to ₹493.42 crore in Q1 FY2026-27 from ₹442.70 crore in Q4 FY2025-26. Tax Expense also rose to ₹112.58 crore in Q1 FY2026-27 from ₹80.41 crore in Q4 FY2025-26.

- Revenue from operations for Q1 FY2026-27 stood at ₹1,625.96 crore.
- Profit Before Tax for Q1 FY2026-27 was ₹446.80 crore.
- Basic Earnings Per Share for Q1 FY2026-27 was ₹26.75 per share.
- Other Expenses in Q1 FY2026-27 were ₹493.42 crore.
- Tax Expense in Q1 FY2026-27 was ₹112.58 crore.

### Bull Case

Ajanta Pharmaceuticals' technical indicators suggest a constructive market setup. The stock is trading above its 20-day and 50-day Simple Moving Averages (SMAs) on a daily basis, with the 50-day SMA showing an upward slope. Furthermore, the Super Trend indicator is signaling a bullish trend across daily, weekly, and monthly timeframes. The stock has also demonstrated significant positive returns over the past year, with a 1-year return of 0.4 and a Year-to-Date (YTD) return of 0.21. This is complemented by a strong 6-month return of 0.17 and a 3-month return of 0.16, indicating sustained upward momentum.

- The stock's closing price of ₹3563.6 on 2026-09-18 is above its 20-day SMA of ₹3538.27 and 50-day SMA of ₹3513.37.
- The 50-day SMA has a positive slope of 20.32 over 5 days, indicating an upward trend.
- The Super Trend indicator is bullish on daily, weekly, and monthly timeframes.
- The stock has achieved a 1-year return of 0.4 and a YTD return of 0.21.
- Recent returns show positive momentum with a 6-month return of 0.17 and a 3-month return of 0.16.

- Domestic pharma market sustains growth momentum, but margins remain key

### Bear Case

While the company's stock has shown positive returns over the past year (40%) and year-to-date (21%), and technical indicators suggest a bullish trend on daily, weekly, and monthly timeframes, certain factors warrant a cautious outlook. The domestic pharmaceutical market, while experiencing growth driven by price hikes and new launches, faces headwinds from weak volumes and uncertainty regarding US tariffs. Sustained margin recovery is highlighted as crucial for sector performance, implying potential pressure on profitability if these factors persist. Additionally, the stock's risk profile includes an annualized volatility of 30% and a maximum drawdown of -21%, indicating potential for significant price fluctuations.

- The domestic pharma market faces uncertainty from weak volumes and US tariffs, with sustained margin recovery being critical for sector performance.
- The stock has experienced a maximum drawdown of -21%, indicating historical periods of significant price decline.
- Annualized volatility stands at 30%, suggesting a higher degree of price fluctuation risk.
- Despite a bullish technical trend, the stock is trading near identified resistance levels, with the nearest at ₹3575.83, representing a 0.34% increase from the current price.

- Domestic pharma market sustains growth momentum, but margins remain key

### FAQs

**What is Ajanta Pharma's recent stock performance and what are its key technical indicators as of September 18, 2026?**

As of September 18, 2026, Ajanta Pharma's stock closed at ₹3563.6. The stock has shown varied returns over different periods: a 2% return in the last day, a 1% return over 10 days, a -4% return in the last month, a 16% return in the last 3 months, and a 17% return in the last 6 months. Year-to-date, the return is 21%, and since the start, it's 19%. Over the last year, the stock has returned 40%. Technically, the daily trend shows the closing price (₹3563.6) is above the 20-day Exponential Moving Average (EMA) of ₹3533.3 and the 50-day EMA of ₹3476.38. The Supertrend indicator is 'bullish' at ₹3460.07. The monthly trend also indicates a 'bullish' Supertrend at ₹2439.53, with the closing price above both the 20-day EMA (₹2981.35) and 20-day Simple Moving Average (SMA) (₹2835.81). The weekly trend shows a 'bullish' Supertrend at ₹3106.73, with the closing price above the 20-day EMA (₹3343.17) and 50-day SMA (₹2964.1).

**What upcoming investor events has Ajanta Pharma scheduled?**

Ajanta Pharma has scheduled two investor meetings in September 2026. The first is a one-on-one meeting at the Jefferies India Forum in New Delhi on September 16, 2026. The second is participation in the PL Capital Mid & Small Cap Conference 2026 at Trident, BKC, on September 28, 2026. Both events are scheduled to commence at 09:00. The company has stated that discussions will be based solely on previously published information.

**What is the status of unclaimed dividends and shares for Ajanta Pharma shareholders?**

Ajanta Pharma Limited published a notice on August 28, 2026, regarding the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF). This action is in accordance with Section 124(6) of the Companies Act, 2013, for shareholders who have not claimed their amounts for the past seven years. The notice invites claims before the shares are transferred. This filing was part of announcements made on August 31, 2026.

- Domestic pharma market sustains growth momentum, but margins remain key
- Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Ajanta Pharma Limited has informed the Exchange about |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- AJANTA PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- NAME OF PROMOTER(S) OR PACS WITH HIM : Ravi P Agrawal, trustee Ravi Agrawal Trust
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹3,503.87
- Risk regime: Price Risk Currently Contained

### Support levels
- 3442.5
- 2932
- 2721.0052734375

### Resistance levels
- 3603.9
- 3666
- 3796

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.80% |
| return_10 | +1.21% |
| return_1m | -3.85% |
| return_1y | +39.84% |
| return_20 | -2.60% |
| return_3m | +15.94% |
| return_5 | +1.24% |
| return_6m | +16.59% |
| return_since_start | +19.01% |
| return_ytd | +21.28% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -20.81% |
| annualized_volatility | +29.93% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue growth accelerates as profit before tax margin expands

Ajanta Pharma Limited reported revenue from operations of ₹1,625.96 crore for the June 2026 quarter, an increase of 24.8% compared with the same quarter a year ago and 14.4% higher than the preceding March 2026 quarter. Profit before tax grew 34.9% year-on-year to ₹446.80 crore, lifting the PBT margin to 27.5% from 25.4%. Net profit (PBT minus tax) was ₹334.22 crore, up 30.9%.

## Revenue Growth

Revenue from operations reached ₹1,625.96 crore, up from ₹1,302.65 crore in the corresponding quarter last year. Sequential growth, which had been modest in the preceding three quarters—ranging between 1.6% and 3.9%—stepped up sharply to 14.4% in the latest quarter, signalling a pickup in the pace of expansion. The year-on-year increase of ₹323.31 crore (24.8%) was the largest absolute and percentage gain across the reported quarterly periods.

## Expense Trends and Profitability

Among the expense items with a year-ago comparison, other expenses rose 32.5% to ₹493.42 crore, faster than the 24.8% revenue growth, while finance costs dropped 39.5% to ₹3.18 crore. The quarter also included other income of ₹70.90 crore.

Cost of materials consumed was ₹296.51 crore, employee benefit expense ₹381.11 crore, and depreciation ₹44.50 crore. The resulting profit before tax of ₹446.80 crore produced a PBT margin of 27.5%, an improvement of roughly 2 percentage points from 25.4% a year earlier. The margin expansion occurred even though other expenses outpaced revenue, aided by the sharply lower finance costs and the other income contribution.

## Tax Expense and Effective Tax Rate

Tax expense rose to ₹112.58 crore from ₹75.79 crore, an increase of 48.5% that exceeded the growth in pre-tax profit. As a result, the effective tax rate moved from 22.9% to 25.2%. This higher tax burden moderated net profit growth: net profit increased 30.9% year-on-year to ₹334.22 crore, compared with the 34.9% rise in profit before tax.

## Earnings per Share

Basic earnings per share (EPS) increased 30.9% to ₹26.75, mirroring net profit growth. Diluted EPS stood at ₹26.72, pointing to negligible dilution from outstanding instruments.

## Management Commentary

Ajanta Pharma reported a strong Q1 FY27 with consolidated revenue up 25% YoY to Rs. 1,626 cr. and PAT up 31% to Rs. 334 cr. The growth was led by India branded generics (up 24% to Rs. 509 cr.), which outperformed the IPM by 36% due to new launches and volume gains, and US generics (up 57% to Rs. 487 cr.) with 51 products on shelf. Africa branded generics grew 30% to Rs. 295 cr., while Asia declined 16% to Rs. 255 cr. due to war impacts. Management declared an interim dividend of Rs. 32 per share and highlighted a 14% 3-year revenue CAGR, with strategic priorities including new product launches, market share gains, and field force productivity enhancement.

## Key Takeaway

The June 2026 quarter delivered a notable acceleration in revenue, with strong year-on-year and sequential gains. Profit before tax grew faster than the top line, expanding the PBT margin, although a higher effective tax rate trimmed the net profit advance relative to pre-tax profit growth.

### Ratios

## Official filings

- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_31082026101535_Newspaperadv31082026.pdf)
- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_31082026114634_Investorparticipation31082026.pdf)
- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20260831_114909008.xml)
- 2026-08-24 — Regulatory Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SASTDisclosure_08242026151348.zip)
- 2026-08-05 — Official Filing: Ajanta Pharma Limited will hold investor meetings on August 11, 2026, and August 13, 2026, in Singapore & Hongkong with Nuvama India Conference 2026. Additionally, a meeting is scheduled for August 18, 2026, in Mumbai with Motilal Annual Global Conference.
- 2026-08-05 — Generic Announcement: Ajanta Pharma Limited will hold investor meetings on August 11-13, 2026, in Singapore and Hong Kong for the Nuvama India Conference 2026, and on August 18, 2026, at Grand Hyatt, Santacruz for the Motilal Annual Global Conference. Discussions will be based on publicly available information. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_05082026165730_Investorparticipation05082026.pdf)
- 2026-08-03 — Official Filing: Ajanta Pharma Limited has uploaded the written transcript of its earnings call held on July 30, 2026. The transcript, pertaining to the first quarter of the 2026-27 fiscal year, is available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_03082026163139_Writtentranscriptofcall03082026.pdf)
- 2026-08-03 — Official Filing: Ajanta Pharma Limited has disclosed the transcripts of its Q1 (Apr-Jun) 2026-27 earnings call on August 3, 2026. The call took place on July 30, 2026, concluding at 17:08:00. The company had previously intimated the exchange about this call on July 20, 2026.
- 2026-07-31 — Official Filing: Ajanta Pharma Limited announced on July 31, 2026, that its financial results for the quarter ended June 30, 2026, were published in the Business Standard and Navakal newspapers. Gillette India Limited's Board of Directors approved its unaudited financial results for the quarter ended June 30, 2026, on July 30, 2026. Timex Group India Limited's Board of Directors approved its unaudited financial results for the quarter ended June 30, 2026, on July 29, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_31072026122501_Newspaperpublication31072026.pdf)
- 2026-07-30 — Official Filing: On July 30, 2026, Ajanta Pharma Limited's Nomination & Remuneration Committee allotted 23,400 equity shares upon exercise of options. This allotment increased the company's paid-up capital to Rs. 24,99,18,048, comprising 12,49,59,024 equity shares of Rs. 2 each. The company will apply for the listing of these new shares. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30072026145402_ESOPallotment30072026.pdf)
- 2026-07-30 — Official Filing: Ajanta Pharma Limited has disclosed an audio recording of an earnings call held on July 30, 2026. The recording, which concluded at 17:08:00, was uploaded to the company's website on July 30, 2026, at 17:27:00. Prior intimation of this earnings call was provided to the exchange on July 20, 2026.
- 2026-07-30 — Official Filing: Ajanta Pharma Limited uploaded an audio recording of its earnings call held on July 30, 2026, at 4:15 p.m. to its website. A written transcript will be submitted later. This disclosure is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30072026174022_AudioRecordingofEarningCall30072026.pdf)
- 2026-07-30 — Official Filing: Ajanta Pharma Limited has set Wednesday, August 5th, 2026, as the record date to determine shareholders eligible for the 1st interim dividend. This decision was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30072026143911_Recorddateintimation30072026.pdf)
- 2026-07-30 — Official Filing: Ajanta Pharma's Board of Directors approved the first quarter unaudited financial results for the period ending June 30, 2026, and declared a first interim dividend of Rs. 32 per share, totaling Rs. 400 crore, with a record date of August 5, 2026. The company reported a 25% increase in revenue to Rs. 1,626 crore and a 31% increase in Profit After Tax (PAT) to Rs. 334 crore for Q1 FY2027 compared to Q1 FY2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30072026144134_BMOutcome30072026.pdf)
- 2026-07-30 — Official Filing: Ajanta Pharma's Board of Directors approved the first quarter unaudited financial results for the period ending June 30, 2026, and declared a first interim dividend of Rs. 32 per share, totaling Rs. 400 crore, with a record date of August 5, 2026. The company reported a 25% increase in revenue to Rs. 1,626 crore and a 31% increase in Profit After Tax (PAT) to Rs. 334 crore for Q1 FY2027 compared to Q1 FY2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30072026143433_BMOutcome30072026.pdf)
- 2026-07-21 — Official Filing: Ajanta Pharma Limited will hold a virtual group meeting for its Q1 FY2027 earnings conference call on July 30, 2026, at 16:15 IST in Mumbai. The meeting is scheduled with Investor Group and the agenda is the Q1 Results. Contact Rajeev Agarwal for details.
- 2026-07-21 — Official Filing: Ajanta Pharma Limited revised the timing of its Earnings Conference Call to 4:15 p.m. IST on July 30, 2026, from the previously scheduled 4:30 p.m. IST. The call will discuss the company's Q1 FY 2027 unaudited financial results. Dial-in information and registration details for the call are provided. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_21072026135237_Investorcall21072026.pdf)
- 2026-07-20 — Official Filing: Ajanta Pharma Limited will hold a board meeting on July 30, 2026, to consider unaudited financial results for the quarter ended June 2026, and an interim dividend. The trading window for the company will be closed from July 1, 2026, to August 1, 2026.
- 2026-07-20 — Official Filing: Ajanta Pharma Limited will hold an earnings conference call for Q1 FY2027 on July 30, 2026, at 16:30 IST. The virtual group meeting will discuss Q1 results and will be held in Mumbai. Dial-in details and a registration link are provided.
- 2026-07-20 — Official Filing: Ajanta Pharma Limited will announce its Q1 FY 2027 unaudited financial results on July 30, 2026, at 16:30 IST. Following the Board meeting, the company will host an Earnings Conference Call at 16:30 IST on the same day to discuss financial performance. A transcript will be available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_20072026145712_Investorcallintimation20072026.pdf)
- 2026-07-17 — Official Filing: Ajanta Pharma Limited held its 47th Annual General Meeting on July 16, 2026, where four resolutions were passed. These included the adoption of financial statements for the year ended March 31, 2026, confirmation of interim dividend, reappointment of a director, and ratification of cost auditors' remuneration for 2025-2027. Voting results showed overwhelming support for all resolutions, with over 99% of votes in favor for each. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_17072026094145_AGMResults17072026.pdf)
- 2026-07-16 — Generic Announcement: The 47th Annual General Meeting of Ajanta Pharma Ltd. was held on July 16, 2026, via video conference, with 62 shareholders attending. The meeting addressed the adoption of financial statements for the year ended March 31, 2026, confirmation of interim dividend as final, re-appointment of Mr. Mannalal B. Agrawal, and ratification of Cost Auditors' remuneration. Results of the e-voting process will be disclosed within two working days. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_16072026155709_AGMProceedings16072026.pdf)
- 2026-07-07 — Official Filing: Ajanta Pharma Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate, received from registrar MUFG Intime India Private Limited, confirms that securities received for dematerialisation were processed and listed on stock exchanges within the prescribed timelines. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_07072026101450_74_5_30062026.pdf)
- 2026-07-02 — Generic Announcement: Ajanta Pharma Limited received the Establishment Inspection Report (EIR) from the USFDA for its Paithan manufacturing facility, classifying the inspection as Voluntary Action Indicated (VAI). The cGMP inspection was conducted from April 13 to April 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_02072026135602_PTNUSFDA_Inspection02072026.pdf)

## News and market events

- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-08-18 — Mint: **Stock market today: Gift Nifty hints a weak start; eight day trading stocks to buy on Tuesday, 18 August** — Sensex and Nifty 50 are set to open lower due to mixed global cues. Brent crude prices have risen amid US-Iran conflict tensions, raising concerns over energy supplies. Analysts suggest cautious trading with key levels for Nifty 50 and Bank Nifty indicating potential selling pressure. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-weak-start-eight-day-trading-stocks-to-buy-on-tuesday-18-august-11787019135761.html)
- 2026-08-13 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Friday** — Sensex gained 114 points while Nifty fell over 40 points on expiry day, reflecting divergent benchmark moves. Softer inflation supported sentiment, but elevated crude prices and geopolitical risks kept investors cautious, with Nifty remaining rangebound between key technical levels. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-friday/articleshow/133218209.cms)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: Hyundai Motor India profit falls 35%, Mankind Pharma margin rises** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)
- 2026-07-30 — CNBC-TV18: **Market close | Stock Market Highlights: Late buying lifts Sensex 273 pts, Nifty settles above 24,300; auto stocks shine** — Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside is key for the Nifty, while the July 17 high of 24,367 is the first hurdle to cross on the upside — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-expiry-infosys-it-eicher-dabur-vedanta-irfc-asian-paints-share-price-liveblog-19957305.htm)
- 2026-07-30 — The Hindu: **Q1 Results Today Live: Vedanta Aluminium Q1 profit zooms, M&M, Gillette, Ajanta Pharma, IRFC, ICRA profit rise, Westlife profit falls, Bajaj Finance, Tata Steel, Vedanta, Torrent Pharma, Hyundai Motor, Swiggy, NSDL to announce Q1 results** — Q1 Results Today, 30th July 2026 Live Updates: Stay tuned for more from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-bajaj-finance-mampm-tata-steel-swiggy-awl-agri-torrent-pharma-hyundai-motor-irfc-mankind-vedanta-gillette-mazagon-thermax-ajanta-nuvama-nsdl-niva-bupa-results-30-july-202/article71280963.ece)
- 2026-07-30 — The Hindu: **Sensex today | Stock Market Live: Sensex, Nifty trade flat; IT stocks outperform in cautious market** — Sensex, Nifty, Stock Price Live Updates: Indian benchmark indices traded in a narrow range on Thursday, with gains in IT stocks led by Persistent Systems, Wipro and Coforge helping offset global uncertainty over the Fed, elevated crude oil prices and geopolitical tensions in West Asia, while investors remained focused on Q1 earnings. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-30th-july-2026/article71281731.ece)
- 2026-07-24 — Mint: **Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%** — Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks. — [Source](https://www.livemint.com/market/stock-market-news/trumps-tariff-policy-abbott-india-ajanta-pharma-to-alembic-pharma-stocks-crash-up-to-4-11784869745089.html)
- 2026-07-23 — Economic Times: **Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors** — Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pharma-stocks-slide-as-trumps-100-generic-drug-tariff-plan-spooks-investors/articleshow/132570049.cms)
- 2026-07-22 — The Hindu: **Sensex today | Stock Market Live: Sensex down 500 pts, Nifty slips to 24,000; Nifty Pharma index in red on Trump's tariffs** — Sensex, Nifty, Share Prices LIVE: Sensex fell 381.02 pts or 0.49% to 77,089.09 at 9.17 am after opening at 77,384.95 from the previous close of 77,470.11; Nifty 50 depreciated 106.75 pts or 0.44% to 24,080.95 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-22nd-july-2026/article71249266.ece)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical formulations.

### Business segments
- **Branded Generics (India):** Focuses on specialty therapeutic segments in India with a direct marketing presence. Primary areas include Cardiology, Dermatology, Ophthalmology, and Pain Management.
- **Branded Generics (Emerging Markets):** Serves countries in Asia, Africa, and the Middle East with a localized product portfolio tailored to local healthcare demands.
- **Generics (USA):** Focuses on niche and complex formulations in the United States, utilizing a selective commercial strategy.
- **Institutional Segment:** Provides anti-malarial products and other essential medicines to institutional buyers and health programs, primarily in Africa.

### Competitive strengths
- Dedicated R&D center developing formulations, APIs, and analytical methodologies.
- Manufacturing facilities producing finished dosages and APIs under global health authority regulations.
- Ability to develop multiple dosage forms including tablets, capsules, injectables, nasal sprays, and topical creams.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%
- [ASTERDM (Healthcare)](https://faxioms.com/stocks/asterdm) — -0.85%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/ajantpharm
Markdown representation: https://faxioms.com/stocks/ajantpharm?render=md